DLBCL

A review of various frontline treatment options in follicular lymphoma and an outline of an algorithm for approaching patients with newly diagnosed follicular lymphoma.

Nathan Fowler, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses managing patients with high-risk follicular lymphoma.

Michelle Fanale, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses patient selection for newly approved agents in T-cell lymphoma.

Results from the phase I portion of the first trial testing axicabtagene ciloleucel, an autologous CD3ζ/CD28-based CAR T-cell therapy, indicate that the regimen can safely be administered and lead to durable CR after more than 12 months in refractory diffuse large B-cell lymphoma.

According to results of a phase I trial, the addition of the CDK 4/6 inhibitor palbociclib can help patients with mantle cell lymphoma overcome resistance to the BTK inhibitor ibrutinib.

The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy.

Alex Herrera, MD, assistant professor, City of Hope, discusses a study investigating the use of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in the treatment of relapsed or treatment-resistant Hodgkin lymphoma during the American Society of Hematology (ASH) Annual Meeting.

Early data from a phase I/II study suggest that the combination of brentuximab vedotin and nivolumab may be an active and well-tolerated outpatient regimen in patients with relapsed/refractory classical Hodgkin lymphoma after failure of standard frontline chemotherapy.

Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma, according to findings from the multicenter phase II ZUMA-1 study.

Kathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).<br /> &nbsp;

Combining obinutuzumab (Gazyva) with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab (Rituxan) plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.

Brentuximab vedotin (Adcetris) induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician&rsquo;s choice of standard therapies, according to findings from the phase III ALCANZA trial.

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) for use as a treatment for patients with refractory classical Hodgkin lymphoma.

Thomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the issues that still need to be addressed in diffuse large B-cell lymphoma.

The FDA has granted a breakthrough therapy designation to the brentuximab vedotin for the treatment of patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large cell lymphoma following at least 1 prior systemic therapy.&nbsp;<br /> &nbsp;

Studies testing immune checkpoint inhibitors in combination with other agents for the treatment of both Hodgkin and non-Hodgkin lymphoma are garnering attention among researchers.

Loretta J. Nastoupil, MD, discusses ongoing lymphoma clinical trials and how practitioners can better identify high- and poor-risk patients with large cell lymphomas.

Two oncologists from Emory University School of Medicine faced off to determine if molecular markers should play a role in the treatment of subgroups of patients with diffuse large B-cell lymphoma.&nbsp;

According to findings from a multicenter randomized trial, chemoradiation for early-stage, low-grade follicular lymphoma led to significant improvement in progression-free survival (PFS) compared with involved-field radiotherapy alone (IFRT).

Pembrolizumab (Keytruda) is associated with an exceptional overall response rate (ORR) in patients with relapsed/refractory Hodgkin lymphoma.

A majority of patients (66%) with classical Hodgkin lymphoma (cHL) who had progressed after receiving autologous stem cell transplant (ASCT) and brentuximab vedotin (adcetris) experienced a response to nivolumab (Opdivo) monotherapy, findings from the phase II CheckMate-205 trial showed when presented at the 2016 ASCO Annual Meeting.

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda) as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

The FDA has granted nivolumab (Opdivo) a priority review for use in previously treated patients with classical Hodgkin lymphoma (cHL), giving the drug the potential to become the first PD-1 inhibitor approved for a hematologic malignancy.

John Leonard, MD, discusses the number of options doctors have to choose from when treating follicular lymphomas.

Expanding on the efficacy shown in numerous single-group studies, a phase II study published in The Lancet Oncology showed lenalidomide significantly increased progression free survivalin patients with relapsed or refractory mantle cell lymphoma.